Bevacizumab, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody approved for CRC in 2004[2], demonstrates primary resistance in a significant proportion of patients[4]. The gene discussed is VEGFA; the disease is colorectal carcinoma.